201 studies found for:    Open Studies | "Leukemia, Myelogenous, Chronic, BCR-ABL Positive"
Show Display Options
Rank Status Study
21 Recruiting Study to Assess Efficacy and Safety of Nilotinib 300mg Twice Daily in Patients With Philadelphia Positive Chronic Myeloid Leukaemia (CML) in Chronic Phase Who Are Intolerant to Prior Tyrosine Kinase Inhibitors.
Condition: Philidelphia Positive Chronic Myeloid Leukaemia
Intervention: Drug: Nilotinib
22 Recruiting Pediatric Chronic Myeloid Leukemia Registry
Condition: Chronic Myeloid Leukemia
Intervention:
23 Recruiting Multicenter Single-arm Pilot Study Evaluating Efficacy of Nilotinib in CML Patients With Molecular Relapse After Glivec Discontinuation Within the Context of the STIM Trials (STIM and STIM2)
Condition: Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Intervention: Drug: Nilotinib
24 Recruiting Dasatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase
Condition: Chronic Myeloid Leukemia
Intervention: Drug: Dasatinib
25 Recruiting De- Escalation and Stopping Treatment of Imatinib, Nilotinib or sprYcel in Chronic Myeloid Leukaemia
Condition: Chronic Myeloid Leukaemia
Interventions: Drug: Imatinib;   Drug: nilotinib;   Drug: dasatinib
26 Not yet recruiting Efficacy and Safety of Imatinib Mesylate as First-line Treatment for the Patients With Chronic Phase of Chronic Myeloid Leukemia
Condition: Chronic Myeloid Leukemia
Intervention: Drug: Imatinib
27 Recruiting Multicenter Trial Estimating the Persistence of Molecular Remission in Chronic Myeloid Leukaemia in Long Term After Stopping Imatinib
Condition: Chronic Myeloid Leukaemia
Intervention: Drug: Imatinib stop
28 Recruiting Evaluating the Safety of Zileuton (Zyflo®) in Combination With Dasatinib (Sprycel®) in Chronic Myelogenous Leukemia
Condition: Chronic Myelogenous Leukemia
Interventions: Drug: Zileuton (Zyflo®)  Dasatinib (Sprycel®);   Drug: Dosing with Zileuton/Dasatinib in CML;   Drug: Daily dosing of Zileuton/Dasatinib;   Drug: Daily dosing with Zileuton/Dasatinib for CML
29 Recruiting Pegylated Interferon Alfa-2b and Nilotinib for Augmentation of Complete Molecular Response in Chronic Myeloid Leukaemia
Condition: Chronic Myeloid Leukaemia
Intervention: Drug: Nilotinib, Pegylated interferon alpha-2b, Imatinib
30 Recruiting Tasigna and Interferon Alpha Evaluation Initiated by the German Chronic Myeloid Leukemia Study Group - the TIGER Study
Condition: Chronic Myeloid Leukemia
Interventions: Drug: Peginterferon α2b;   Drug: Nilotinib
31 Recruiting Discontinuation of Dasatinib in Patients With Chronic Myeloid Leukemia-CP Who Have Maintained Complete Molecular Remission for Two Years; Dasatinib Stop Trial
Condition: Chronic Myeloid Leukemia
Intervention: Drug: Dasatinib
32 Recruiting A Phase 1B Study to Investigate the Safety and Preliminary Efficacy for the Combination of Dasatinib Plus Nivolumab in Patients With Chronic Myeloid Leukemia
Condition: Chronic Myeloid Leukemia
Interventions: Drug: Dasatinib;   Drug: Nivolumab
33 Recruiting Patterns of ABL Mutation in Asian With Imatinib Resistant Chronic Myeloid Leukemia and Ph Positive Acute Lymphocytc Leuekmia Patients (AMICA)
Condition: Chronic Myeloid Leukemia or Ph Positive ALL
Intervention:
34 Recruiting Open-Label Study Evaluating Dasatinib Therapy Discontinuation in Patients With Chronic Phase Chronic Myeloid Leukemia With Stable Complete Molecular Response
Condition: Chronic Phase Chronic Myeloid Leukemia
Intervention: Drug: Dasatinib
35 Recruiting Arsenic Trioxide and Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia (CML)
Condition: Chronic Myelogenous Leukemia
Intervention: Drug: Arsenic trioxide
36 Unknown  Comparing Imatinib Standard Dose With Imatinib High Dose Induction in Pretreated Chronic Myeloid Leukemia (CML) Patients in Chronic Phase
Condition: Chronic Myeloid Leukemia
Intervention: Drug: Imatinib
37 Recruiting Assessment Of Gh-Igf-1 Axis In Children With Chronic Myelogenous Leukemia (CML) In Remission
Conditions: Chronic Myelogenous Leukemia;   Short Stature
Intervention: Drug: Growth Hormone
38 Recruiting Ruxolitinib in Combination With Nilotinib in Chronic Myeloid Leukemia (CML) Patients
Condition: Chronic Phase Chronic Myeloid Leukemia
Interventions: Drug: Nilotinib;   Drug: Ruxolitinib
39 Recruiting Allogeneic SCT for CML, TKI Failure After TKI Failure
Condition: Chronic Myeloid Leukemia
Intervention:
40 Recruiting Observational Study of Conception/Pregnancy in Adult Patients With CML Treated With Tyrosine Kinase Inhibitors
Conditions: Chronic Myeloid Leukemia;   Pregnancy
Intervention:

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years